

Takeda shows it's serious about coeliac disease



[Amy Brown](#)

Takeda this week doubled down on a second coeliac disease project, [buying Pvp Biologics](#) only four months after licensing another candidate from [Cour Pharmaceuticals](#). The Japanese company is clearly serious about this space, a field of research that has seen increasing evidence of big pharma interest in the past 12 months or so. Last year [Glaxosmithkline bought out Sitari](#) for its enzymatic approach, while [Roche signed a deal with Parvus](#), which is using T cells to achieve immune sensitisation. Still, these collaborations have yet to make it into the clinic; in contrast the projects now owned by Takeda are heading into further mid-stage testing. Pvp and Cour have taken different tacks to treating the extreme immune response seen in sufferers of coeliac disease: the former has developed a “super glutenase” that degrades ingested gluten, while the latter uses encapsulated gluten antigens to induce immune tolerance. The apparent big pharma interest here means that data from the remaining independent players will be watched closely; although another conclusion is that the recent spate of deal making means that business development teams have already given more advanced projects from the likes of Innovate and Immunogenics a close look, and moved on.

Notable coeliac disease projects

Company/sponsor	Project	Mechanism	NCT ID	Notes
Phase III				
Innovate Biopharmaceuticals	INN-202	Intestinal tight junction regulator	NCT03569007	Trial recruiting, completion date in 2021
Phase II				
Immunogenics	IMGX-003	Recombinant gluten-specific protease	NCT03585478; NCT04243551	Two NIH funded phase II/IIb trials ongoing, results due late 2020 and '21.
Takeda (Cour Pharmaceuticals)	TAK-101 (CNP-1010)	Gliadin desensitiser	NCT03738475	Dose ranging studies planned.
Igy Life Sciences/Vetanda	AGY (food supplement)	Gliadin neutraliser (anti-gluten immunoglobulin Y)	NCT03707730	Primary completion due late 2022.
Dr Falk/Zedira	ZED1227	TG2 inhibitor	2017-002241-30	Started late 2018, no updates since.
Provention (Amgen)	PRV-015 (AMG 714)	Anti-IL-15 Mab	-	Phase IIb guided to start H1'20
Phase I				
Takeda (PVP Biologics)	TAK-062 (Kuma-062)	Glutenase	NCT03701555	Phase IIb planned
Preclinical				
Parvus/Roche	Parvus-Roche research project	T cell-targeted immunological tolerance	n/a	No news since Roche deal in May 2019.

Source: EvaluatePharma, clinicaltrials.gov.